Feb 21, 2012
MOUNTAIN VIEW, Calif. - Feb. 21, 2012 - Complete Genomics
Inc. (NASDAQ: GNOM) today announced that the company will
be included in MIT's Technology Review TR50, an annual list
of the 50 most innovative technology companies in the
world. It is the third-consecutive year that Complete
Genomics has been named to the list.
Companies are nominated by Technology Review that have
demonstrated original and valuable technology, have brought
that technology to market at a significant scale, and have
influenced competitors during the past year. The TR50 list
includes companies in the energy, computing and Internet,
biomedicine, and materials industries that represent
commercial innovations most likely to change lives around
"The new sequencing projects that Complete Genomics has
undertaken, enabled by its advanced sequencing technology
and computation platform, will make important contributions
to understanding diseases such as cancer," said Jason
Pontin, editor in chief and publisher of Technology Review.
For researchers and healthcare organizations making strides
toward genomic medicine, Complete Genomics provides whole
human genome sequencing as a service using its proprietary
sequencing platform. In 2011, the company sequenced and
delivered more than 3,000 human genomes to its customers.
In August, Complete Genomics announced a project to
sequence more than 1,000 additional genomes for the
National Cancer Institute's (NCI's) pediatric cancer study.
The project is part of an NCI initiative that seeks to use
genomics technologies to identify valid therapeutic targets
in childhood cancers so new, more effective treatments can
Complete Genomics also announced in August that it would be
partnering with Inova Health System to sequence 1,500
genomes from 500 babies and their parents in an effort to
identify prognostic, diagnostic and therapeutic targets for
pre-term delivery and potentially other associated defects.
And in October, the company announced a collaboration with
Scripps Health, under which Complete Genomics will
sequence, at its own cost, the whole human genomes of 1,000
participants in the Wellderly Study. The Wellderly Study
aims to unlock the genetic secrets of lifelong health by
sequencing the genomes of healthy people age 80 and above.
"Our customers are doing great work discovering the genomic
causes of disease and taking the first steps toward
personalized medicine," said Dr. Clifford Reid, chairman,
president and CEO of Complete Genomics. "We are honored,
for the third year in a row, to be included in the TR50
alongside so many other innovative companies."
About Technology Review, Inc.
Technology Review is an independent media company owned by
the Massachusetts Institute of Technology. More than three
million people around the globe read our publications, in
five languages and on a variety of digital and print
platforms. We publish Technology Review magazine, the
world's oldest technology magazine (established 1899);
daily news, analysis, opinion, and video on
www.technologyreview.com and several mobile apps; Business
Impact, which explains how new technologies are
transforming companies, disrupting markets, or creating
entirely new industries; and live events including the
annual Emtech MIT conference. Technology Review also owns
the MIT Enterprise Forum, a community and events
organization that fosters technology entrepreneurship with
28 chapters worldwide.
About Complete Genomics
Complete Genomics is the whole human genome sequencing
company that has developed and commercialized an innovative
DNA sequencing service. The Complete Genomics Analysis
Platform (CGA Platform) combines Complete Genomics'
proprietary human genome sequencing technology with
advanced informatics and data management software.
Additional information can be found at
# # #
Jennifer Turcotte, Vice President of Marketing | Complete
Genomics, Inc. | 650.943.2846 | [email protected]
Lisa Osborne, Account Director | Waggener Edstrom Worldwide
Healthcare | 202.261.7806 | [email protected]